Poland· PL-100367737

Coagadex

A coagulation factor x product containing factor x coagulationis humanus, registered in Poland by BPL Bioproducts Laboratory GmbH. The same ATC class is registered in 9 of our 19 countries.

ATC B02BD13

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedCoagadexATCB02BD13REGISTER NO.PL-100367737PACKS LISTED0CHECKEDSeptember 27, 2026

Where it is registered

Coagulation factor x is registered in 9 of 19 countries.

Countries holding a registration under ATC B02BD13 (coagulation factor x), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 6 of them publish a price we can compare per daily dose

Coagulation factor x · ATC B02BD13

9 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Factor X coagulationis humanus
Manufacturer
BPL Bioproducts Laboratory GmbH
Country
Poland (PL)
ATC code
B02BD13
ATC class
Coagulation factor X
Defined daily dose
1.75 TSD, E
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

8 interactions on record for coagulation factor x.

Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Coagulation factor x · interactions on record

8 records

  • 2 severe
  • 6 moderate

Most severe, free to view

  • CarfilzomibL01XG02severe
  • CarfilzomibL01XX45severe
  • RivaroxabanB01AF01moderate
  • ApixabanB01AF02moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/a18626fa-1262-4711-b860-a0320a354cbe
GET /v1/drugs/a18626fa-1262-4711-b860-a0320a354cbe?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Proszek i rozpuszczalnik do sporządzania roztworu do wstrzykiwań",
  "source": "urpl",
  "strength": "250 j.m.",
  "packaging": "Rpz ¦ EU/1/16/1087/001 ¦ 114863\n1 fiol.  proszku + 1 fiol. rozp. + zestaw do transferu",
  "substance": "Factor X coagulationis humanus 250 j.m.",
  "common_name": "Factor X coagulationis humanus",
  "pl_product_id": "100367737",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}

See everything about coagulation factor x.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.